Abstract:Hepatorenal syndrome (HRS) is a serious form of renal dysfunction in patients with cirrhosis and ascites. It is an important component of the acute-on-chronic liver failure (ACLF) syndrome. Significant recent changes in the understanding of the pathophysiology of renal dysfunction in cirrhosis include the role of inflammation in addition to hemodynamic changes. The term acute kidney injury (AKI) is now adopted to include all functional and structural forms of acute renal dysfunction in cirrhosis, with various stages describing the severity of the condition. Type 1 hepatorenal syndrome (HRS1) is renamed HRS-AKI, which is stage 2 AKI [doubling of baseline serum creatinine (sCr)] while fulfilling all other criteria of HRS1. Albumin is used for its volume expanding and anti-inflammatory properties to confirm the diagnosis of HRS-AKI. Vasoconstrictors are added to albumin as pharmacotherapy to improve the hemodynamics. Terlipressin, although not yet available in North America, is the most common vasoconstrictor used worldwide. Patients with high grade of ACLF treated with terlipressin are at risk for respiratory failure if there is pretreatment respiratory compromise. Norepinephrine is equally effective as terlipressin in reversing HRS1. Recent data show that norepinephrine may be administered outside the intensive care setting, but close monitoring is still required. There has been no improvement in overall or transplant-free survival shown with vasoconstrictor use, but response to vasoconstrictors with reduction in sCr is associated with improvement in survival. Non-responders to vasoconstrictor plus albumin will need liver transplantation as definite treatment with renal replacement therapy as a bridge therapy. Combined liver and kidney transplantation is recommended for patients with prolonged history of AKI, underlying chronic kidney disease or with hereditary renal conditions. Future developments, such as the use of biomarkers and metabolomics, may help to identify at risk patients with earlier diagnosis to allow for earlier treatment with improved outcomes.

Research progress in diagnosis and treatment of hepatorenal syndrome

Management of hepatorenal syndrome in liver cirrhosis: a recent update

Progress on treatment of hepatorenal syndrome

Clinical advances on hepatorenal syndrome research

Hepatorenal Syndrome in Cirrhosis

Hepatorenal syndrome-vasoconstrictor or vasodilator?

Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation

Management of hepatorenal syndrome and associated outcomes: a systematic reviews

Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy

Improving Outcomes in Hepatorenal Syndrome-Acute Kidney Injury With Early Diagnoses and Implementation of Approved Treatment Regimens

Improving the Management of Hepatorenal Syndrome-Acute Kidney Injury Using an Updated Guidance and a New Treatment Paradigm

Treatment and outcome of hepatorenal syndrome in Japan: a retrospective cohort study using a national inpatient database

Study on the Risk Factors of the Occurrence of Hepato Renal Syndrome for Patients with Acute on Chronic Hepatitis B Liver Failure

Management of hepatorenal syndrome and treatment-related adverse events

Acute kidney injury and hepatorenal syndrome in cirrhosis

Analysis of Relationship of Chronic Severe Hepatitis with Hepatorenal Syndrome

Outcome Of Patients With Hepato-Renal Syndrome Type 1 After Liver Transplantation: Hangzhou Experience

From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury

The use of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for diagnosis of hepato-renal syndrome in advanced cirrhotic patients

Nursing Care of Continuous Veno-Venous Hemofiltration for Patients with Hepatorenal Syndrome

Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group